Crosslink Therapeutics files Form D for $5.5 million offering

Crosslink Therapeutics Inc., a Delaware corporation incorporated within the last five years, in 2021¹, filed a Form D with the SEC disclosing an exempt securities offering. The filing lists the company's principal place of business at 349-351 Newbury Street in Boston, Massachusetts¹.

The offering relied on the Rule 506(b) exemption¹. According to the filing, this was a new notice with a date of first sale of 2026-10-08¹.

The company reported a total offering amount of $5,500,000, with the total amount sold also at $5,500,000, leaving $0 remaining to be sold¹. The filing states the total number of investors who already invested in the offering was 8¹.

The securities offered were described as an option, warrant or other right to acquire another security, and a security to be acquired upon exercise of option, warrant or other right to acquire security¹. The filing indicates the offering was not made in connection with a business combination transaction such as a merger, acquisition or exchange offer¹.

No sales commissions or finder's fees were reported, as sales commissions and finders' fees were both listed at $0¹. Similarly, proceeds used for payments to executive officers, directors, or promoters named in the filing were listed at $0¹.

The filing was signed by Ronald D. Seidel, III, identified as Chief Executive Officer, and dated 2026-10-20¹. Related persons listed in the filing include Ronald D. Seidel, III as an executive officer and director, along with directors Andrew King, Lou Tartaglia, Rodolfo Chaparro, David Fallace, and Cameron Gallagher¹. The company's industry group was marked as pharmaceuticals¹.